

# HealthAlliance**MEDICARE**

## **PURPOSE OF THE POLICY**

To establish guidelines to evaluate the appropriateness of override of the criteria-based drug policy

## **STATEMENT OF THE POLICY**

Regranex will only be covered if the following criteria are met and applies to new starts only for Medicare Part D members.

## **PROCEDURES**

### **1. Criteria**

1.1 An authorization is needed for each occurrence/recurrence of a diabetic ulcer

### **2. Additional information**

2.1 Authorization for becaplermin is necessary due to its limited efficacy in clinical trials. Based upon the Steed, et al (1995) efficacy study in lower extremity diabetic ulcers, complete healing rates were 15 percent after eight weeks, and 25 percent after 10 weeks. Becaplermin is only for use in patients with chronic and non-healing lower-extremity diabetic ulcers, only as adjunct to surgical debridement.